Corium International, Inc

Company Summary

A commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products. Prior to its IPO, Corium was a portfolio company of Essex Woodlands and Aphelion Capital.

Transaction Overview

On 2 April, 2014, Corium announced that it had completed a high-yield notes offering in the amount of $35 million, led by Healthcare Royalty Partners
On 6 April, 2015, Corium completed an Initial Public Offering (“IPO”) of Common Stock in the amount of $52 million, underwritten by Jeffreys, Cowen and Needham

‍

Significance of the Transaction

The Notes financing permits the Company to expand its specialty contract manufacturing capabilities and broaden existing strategic partnerships with global generics manufacturers The IPO allows the Company to pursue advanced clinical development of its proprietary CorPlex and MicroCor transdermal product candidates, in addition to providing attractive liquidity to shareholders

Healthios Role

If you would like to learn more information about this transaction contact us below.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Private Placement

Corium International, Inc

Has issued $35 million in interest-bearing high yeild securities

The undersigned acted as strategic advisor to Corium International